drugset / Trial / NCT06517797

One-Year Study of S1B-509 vs Placebo for Weight Loss

NCT06517797

Phase 2 Not yet recruiting 210 enrolled S1 Biopharma, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study to test whether S1B-509 given orally daily helps people with overweight or obesity to lose more weight than with placebo over a year.

Timeline

Start
2025-10-15
Primary completion
2027-06-15
Completion
2027-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule Oral
Subject Trazodone Small molecule Oral

Indications